Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aviv Pudipeddi, Viraj Kariyawasam, Craig Haifer, Brandon Baraty, Sudarshan Paramsothy & Rupert WL Leong. (2019) Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 18:5, pages 357-367.
Read now
Read now
Mohammed Razvi & Mark Lazarev. (2018) Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 18:3, pages 263-272.
Read now
Read now
Lieven Pouillon, Peter Bossuyt & Laurent Peyrin-Biroulet. (2016) Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion on Biological Therapy 16:10, pages 1277-1290.
Read now
Read now
Articles from other publishers (27)
Ximeng Wang & Jiande DZ Chen. (2023) Therapeutic potential and mechanisms of sacral nerve stimulation for gastrointestinal diseases. Journal of Translational Internal Medicine 11:2, pages 115-127.
Crossref
Crossref
Sally Lawrence, Farah Faytrouni, Rachel E. Harris, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Vikki Garrick, Lee Curtis, Lisa Gervais, Rachel Tayler, Marliss Riou, Richard Hansen, Kevan Jacobson & Richard K. Russell. (2022) Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing. Journal of Pediatric Gastroenterology & Nutrition 75:5, pages 601-607.
Crossref
Crossref
Sebastiaan ten Bokkel Huinink, Djuna C. de Jong, Daan Nieboer, Doranne Thomassen, Ewout W. Steyerberg, Marcel G.W. Dijkgraaf, Alexander G.L. Bodelier, Rachel L. West, Tessa E.H. Römkens, Frank Hoentjen, Rosalie C. Mallant, Bas A.C. van Tuyl, Wout G.N. Mares, Frank H.J. Wolfhagen, Gerard Dijkstra, Jurriën G.P. Reijnders, Nanne K. de Boer, Adriaan C.I.T.L. Tan, Petra G.A. van Boeckel, Greetje J. Tack, Dirk P. van Asseldonk, Geert R.A.M. D’Haens, C Janneke van der Woude, Marjolijn Duijvestein & Annemarie C de Vries. (2022) Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease. European Journal of Gastroenterology & Hepatology 34:10, pages 983-992.
Crossref
Crossref
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, Benjamin Cohen, Timothy Ritter, Bruce Sands, Corey Siegel, John Valentine, Michelle Smith, Niels Vande Casteele, Marla Dubinsky & Adam Cheifetz. (2022) Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open 12:4, pages e057656.
Crossref
Crossref
Edouard Louis. (2022) Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros. Inflammatory Intestinal Diseases 7:1, pages 64-68.
Crossref
Crossref
Seiji Yokoyama, Teita Asano, Katsumasa Nagano, Hiroaki Tsuchiya, Masayuki Takagishi, Shigeharu Tsujioka, Naomi Miura & Takayuki Matsumoto. (2021) Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan. Journal of Gastroenterology and Hepatology 36:11, pages 3069-3076.
Crossref
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeysh, M. V. Shapina & O. B. Shchukina. (2020) Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion. Almanac of Clinical Medicine 48:6, pages 422-436.
Crossref
Crossref
Andrew Dermawan, Kenji So, Kannan Venugopal & Sherman Picardo. (2020) Infliximab-induced optic neuritis. BMJ Case Reports 13:12, pages e236041.
Crossref
Crossref
Louise Gaboriau, Jean-Baptiste Davion, Sandrine Combret, Bénédicte Lebrun-Vignes, Fanny Rocher, Franck Rouby, Florence Renaud, Sandrine Morell-Dubois & Sophie Gautier. (2020) Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases. Neuromuscular Disorders 30:11, pages 915-920.
Crossref
Crossref
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina & O. B. Shchukina. (2020) Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion. Modern Rheumatology Journal 14:3, pages 7-18.
Crossref
Crossref
Antoine Chupin, Vittorio Perduca, Antoine Meyer, Christophe Bellanger, Franck Carbonnel & Catherine Dong. (2020) Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics.
Crossref
Crossref
Jiafei Cheng, Hong Shen, Reezwana Chowdhury, Tsion Abdi, Florin Selaru & Jiande D Z Chen. (2020) Potential of Electrical Neuromodulation for Inflammatory Bowel Disease. Inflammatory Bowel Diseases 26:8, pages 1119-1130.
Crossref
Crossref
Konstantinos Papamichael, Adam S Cheifetz & Peter M Irving. (2020) New role for azathioprine in case of switching anti-TNFs in IBD. Gut 69:7, pages 1165-1167.
Crossref
Crossref
Konstantinos Papamichael & Adam S. Cheifetz. (2020) Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Current Opinion in Rheumatology 32:4, pages 371-379.
Crossref
Crossref
Edouard Louis. (2020) Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Frontiers in Medicine 6.
Crossref
Crossref
Vipul Jairath, John W.D. McDonald & Brian G. Feagan. 2019. Evidence-based Gastroenterology and Hepatology 4e. Evidence-based Gastroenterology and Hepatology 4e
173
186
.
Antoine MeyerJérémie RudantJérôme DrouinAlain WeillFranck CarbonnelJoël Coste. (2018) Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. Annals of Internal Medicine 170:2, pages 99.
Crossref
Crossref
Stéphane Nahon, Pierre Lahmek, Gilles Macaigne, Bruno Lesgourgues & Thierry Paupard. (2018) Crohn's disease treatment practices in France in1999–2013: A prospective survey in non-academic hospitals. Clinics and Research in Hepatology and Gastroenterology 42:5, pages 470-477.
Crossref
Crossref
Hai Yun Shi & Siew Chien Ng. (2018) The state of the art on treatment of Crohn’s disease. Journal of Gastroenterology 53:9, pages 989-998.
Crossref
Crossref
Patrícia Guedes Garcia, Liliana Andrade Chebli, Tarsila Campanha da Rocha Ribeiro, Pedro Duarte Gaburri, Fabio Heleno de Lima Pace, Kátia Valéria Bastos Dias Barbosa, Lívia Almeida Costa, William de Almeida Cruz, Isabelle Carvalho de Assis, Bernardo Rodriguez Mendes Moraes, Alexandre Zanini & Julio Maria Fonseca Chebli. (2018) Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting. International Journal of Colorectal Disease 33:9, pages 1285-1294.
Crossref
Crossref
Alessandro Armuzzi, Sandro Ardizzone, Livia Biancone, Fabiana Castiglione, Silvio Danese, Paolo Gionchetti, Ambrogio Orlando, Fernando Rizzello, Maria Lia Scribano, Maurizio Vecchi & Marco Daperno. (2018) Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Disease 50:7, pages 653-660.
Crossref
Crossref
Yan Epelboym, Paul B. Shyn, Jeffrey Forris Beecham Chick, Matthew J. Hamilton, Stacy D. O'Connor, Stuart G. Silverman & Chun K. Kim. (2017) Crohn Disease. Clinical Nuclear Medicine 42:11, pages 837-841.
Crossref
Crossref
Iris DetrezThomas Van StappenMaría D. Martín Arranz, Kostas PapamichaelAnn Gils. (2017) Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Therapeutic Drug Monitoring 39:4, pages 344-349.
Crossref
Crossref
Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D’Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci, Annalisa Aratari, Fabrizio Bossa, Maria Cappello, Andrea Cassinotti, Alberto Chiriatti, Gionata Fiorino, Vincenzo Formica, Luisa Guidi, Alessandra Losco, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Roberta Pica, Mariabeatrice Principi, Sara Renna, Chiara Ricci, Antonio Rispo, Francesca Rogai, Loredana Sarmati, Franco Scaldaferri, Luisa Spina, Rosy Tambasco, Anna Testa & Angelo Viscido. (2017) Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 49:4, pages 338-358.
Crossref
Crossref
Michaela GolicFriedrich C. LuftRalf Dechend. (2016) Tumor Necrosis Factor-α, Uterine Natural Killer Cells, and Pregnancy. Hypertension 68:5, pages 1108-1109.
Crossref
Crossref
Lydia C. T. Buer, Bjørn A. Moum, Milada Cvancarova, David J. Warren, Asle W. Medhus & Marte Lie Høivik. (2016) Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. Journal of Crohn's and Colitis, pages jjw166.
Crossref
Crossref
Chaya Shwaartz, Adam C. Fields, Maximiliano Sobrero, Brian D. Cohen & Celia M. Divino. (2016) Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. Journal of Gastrointestinal Surgery 20:9, pages 1636-1642.
Crossref
Crossref